$EYPT
EyePoint Pharmaceuticals, Inc. Stock $eypt

$eypt Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000119312517162489 Filed on May 08, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$701.0K	$590.0K	$324.0K
YoY Change	130.59%	82.1%	-1.22%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.620M	$2.430M	$2.350M
YoY Change	-1.5%	3.4%	15.2%
% of Gross Profit
Research & Development	$4.210M	$3.324M	$3.074M
YoY Change	2.68%	8.13%	-7.94%
% of Gross Profit
Depreciation & Amortization	$210.0K	$210.0K	$220.0K
YoY Change	-16.0%	-4.55%	4.76%
% of Gross Profit
Operating Expenses	$6.840M	$5.750M	$5.420M
YoY Change	1.18%	6.09%	0.74%
Operating Profit	-$6.136M	-$5.160M	-$5.096M
YoY Change	-4.96%	1.26%	0.87%
Interest Expense	$20.00K	$20.00K	$20.00K
YoY Change	-33.33%	0.0%	100.0%
% of Operating Profit
Other Income/Expense, Net		$20.00K	$21.00K
YoY Change		-4.76%	110.0%
Pretax Income	-$6.120M	-$5.140M	-$5.075M
YoY Change	-4.82%	1.28%	0.65%
Income Tax	$0.00	$0.00	-$34.00K
% Of Pretax Income
Net Earnings	-$6.116M	-$5.140M	-$5.041M
YoY Change	-4.24%	1.96%	0.86%
Net Earnings / Revenue	-872.47%	-871.19%	-1555.86%
Basic Earnings Per Share			-$0.15
Diluted Earnings Per Share	-$1.581M	-$1.494M	-$0.15
COMMON SHARES
Basic Shares Outstanding	39.27M shares	34.18M shares	33.54M shares
Diluted Shares Outstanding			33.54M shares

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.90M	$15.40M	$33.30M
YoY Change	-41.72%	-53.75%	5.05%
Cash & Equivalents	$16.90M	$12.87M	$24.87M
Short-Term Investments	$0.00	$2.500M	$8.400M
Other Short-Term Assets	$600.0K	$800.0K	$500.0K
YoY Change	20.0%	60.0%	-50.0%
Inventory
Prepaid Expenses
Receivables	$300.0K	$300.0K	$500.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$17.74M	$16.47M	$34.28M
YoY Change	-40.79%	-51.95%	3.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$313.0K	$241.0K	$311.0K
YoY Change	7.93%	-22.51%	11.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$300.0K	$300.0K	$300.0K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$937.0K	$1.035M	$1.887M
YoY Change	-43.42%	-45.15%	-28.11%
TOTAL ASSETS
Total Short-Term Assets	$17.74M	$16.47M	$34.28M
Total Long-Term Assets	$937.0K	$1.035M	$1.887M
Total Assets	$18.68M	$17.51M	$36.17M
YoY Change	-40.93%	-51.6%	1.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.016M	$741.0K	$571.0K
YoY Change	-25.46%	29.77%	-29.68%
Accrued Expenses	$4.224M	$3.943M	$3.378M
YoY Change	17.89%	16.73%	146.39%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.290M	$4.940M	$3.968M
YoY Change	3.87%	24.5%	78.9%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$51.00K	$100.0K	$5.600M
YoY Change	-99.09%	-98.21%	0.0%
Total Long-Term Liabilities	$51.00K	$100.0K	$5.600M
YoY Change	-99.09%	-98.21%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.290M	$4.940M	$3.968M
Total Long-Term Liabilities	$51.00K	$100.0K	$5.600M
Total Liabilities	$5.341M	$4.995M	$9.612M
YoY Change	-50.26%	-48.03%	22.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$310.8M	-$304.6M	-$285.8M
YoY Change	6.37%	6.56%	7.65%
Common Stock	$323.3M	$316.3M	$311.5M
YoY Change	3.55%	1.53%	1074027.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.34M	$12.51M	$26.55M
YoY Change
Total Liabilities & Shareholders Equity	$18.68M	$17.51M	$36.17M
YoY Change	-40.93%	-51.6%	1.3%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$6.116M	-$5.140M	-$5.041M
YoY Change	-4.24%	1.96%	0.86%
Depreciation, Depletion And Amortization	$210.0K	$210.0K	$220.0K
YoY Change	-16.0%	-4.55%	4.76%
Cash From Operating Activities	-$4.450M	-$4.540M	-$4.300M
YoY Change	2.3%	5.58%	8.59%
INVESTING ACTIVITIES
Capital Expenditures	-$130.0K	-$10.00K	-$30.00K
YoY Change	225.0%	-66.67%	-25.0%
Acquisitions
YoY Change
Other Investing Activities	$2.500M	$3.350M	$1.470M
YoY Change	-147.35%	127.89%	-153.65%
Cash From Investing Activities	$2.380M	$3.330M	$1.430M
YoY Change	-144.74%	132.87%	-151.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$17.80M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.100M	2.390M	16.53M
YoY Change	4983.33%	-85.54%
NET CHANGE
Cash From Operating Activities	-4.450M	-4.540M	-4.300M
Cash From Investing Activities	2.380M	3.330M	1.430M
Cash From Financing Activities	6.100M	2.390M	16.53M
Net Change In Cash	4.030M	1.180M	13.66M
YoY Change	-142.2%	-91.36%	-302.67%
FREE CASH FLOW
Cash From Operating Activities	-$4.450M	-$4.540M	-$4.300M
Capital Expenditures	-$130.0K	-$10.00K	-$30.00K
Free Cash Flow	-$4.320M	-$4.530M	-$4.270M
YoY Change	0.23%	6.09%	8.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39268692	shares
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24867000
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	26553000
CY2016Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2016Q1	psdv	Warrants Outstanding And Exercisable Weighted Average Exercise Price WarrantsOutstandingAndExercisableWeightedAverageExercisePrice	2.50
CY2016Q1	psdv	Warrants To Purchase Common Shares Outstanding And Exercisable WarrantsToPurchaseCommonSharesOutstandingAndExercisable	623605	shares
CY2017Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-304582000
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	800000
CY2017Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Security Deposit SecurityDeposit	150000
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000
CY2017Q1	psdv	Cash And Cash Equivalents And Marketable Securities Fair Value CashAndCashEquivalentsAndMarketableSecuritiesFairValue	15400000
CY2017Q1	psdv	Warrants Outstanding And Exercisable Weighted Average Exercise Price WarrantsOutstandingAndExercisableWeightedAverageExercisePrice	2.50
CY2017Q1	psdv	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	2166000
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1052000
CY2017Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	34832000
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0
CY2017Q1	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	13484000
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35668685	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35668685	shares
CY2017Q1	us-gaap	Assets Assets	17505000
CY2017Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	55000
CY2017Q1	us-gaap	Assets Current AssetsCurrent	16470000
CY2017Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	10985000
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3400000
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	316233000
CY2017Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	2499000
CY2017Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	2499000
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12871000
CY2017Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	300000
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	35000
CY2017Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	741000
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	256000
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	715000
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	824000
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3943000
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q1	us-gaap	Other Assets OtherAssets	104000
CY2017Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	34292000
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2499000
CY2017Q1	us-gaap	Liabilities Liabilities	4995000
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17505000
CY2017Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	540000
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4940000
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10000
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	241000
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	12510000
CY2017Q1	us-gaap	Restructuring Reserve RestructuringReserve	0
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.35
CY2017Q1	psdv	Warrants To Purchase Common Shares Outstanding And Exercisable WarrantsToPurchaseCommonSharesOutstandingAndExercisable	623605	shares
CY2015Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	39710000
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19121000
CY2015Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	37785000
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	23368000
CY2015Q2	psdv	Warrants Outstanding And Exercisable Weighted Average Exercise Price WarrantsOutstandingAndExercisableWeightedAverageExercisePrice	3.67
CY2015Q2	psdv	Warrants To Purchase Common Shares Outstanding And Exercisable WarrantsToPurchaseCommonSharesOutstandingAndExercisable	1176105	shares
CY2016Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1314000
CY2016Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	36196000
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000
CY2016Q2	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	27535000
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34172919	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34172919	shares
CY2016Q2	us-gaap	Assets Assets	31619000
CY2016Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	60000
CY2016Q2	us-gaap	Assets Current AssetsCurrent	29963000
CY2016Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	13856000
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	312208000
CY2016Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	13681000
CY2016Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	13679000
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15313000
CY2016Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	488000
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	34000
CY2016Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5585000
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1363000
CY2016Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	147000
CY2016Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	535000
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	852000
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3583000
CY2016Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q2	us-gaap	Other Assets OtherAssets	114000
CY2016Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	35094000
CY2016Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	13679000
CY2016Q2	us-gaap	Liabilities Liabilities	10738000
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31619000
CY2016Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1102000
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5093000
CY2016Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	56000
CY2016Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	290000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-30000
	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	-1364000
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	6108000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-28000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12440000
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	131000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2404000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	109000
	us-gaap	Payments For Restructuring PaymentsForRestructuring	659000
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	2000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>Operations and Basis of Presentation</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> The accompanying condensed consolidated financial statements of pSivida Corp. and subsidiaries (the “Company”) as of March 31, 2017 and for the three and nine months ended March 31, 2017 and 2016 are unaudited. Certain information in the footnote disclosures of these financial statements has been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”). These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and footnotes included in its Annual Report on Form <font style="WHITE-SPACE: nowrap">10-K</font> for the fiscal year ended June 30, 2016 (“fiscal 2016”). In the opinion of management, these statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended June 30, 2016, and include all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods indicated. The preparation of financial statements in accordance with U.S. generally accepted accounting principles (“GAAP”) requires management to make assumptions and estimates that affect, among other things, (i) reported amounts of assets and liabilities; (ii) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (iii) reported amounts of revenues and expenses during the reporting period. The results of operations for the three and nine months ended March 31, 2017 are not necessarily indicative of the results that may be expected for the entire fiscal year or any future period.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> The Company currently develops proprietary sustained-release drug products for the treatment of chronic eye diseases. The Company’s approved products and product candidates deliver drugs at a controlled and steady rate for months or years. The Company has developed three of only four sustained-release products approved by the U.S. Food and Drug Administration (“FDA”) for treatment of <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">back-of-the-eye</font></font></font> diseases. Durasert™ three-year <font style="WHITE-SPACE: nowrap">non-erodible</font> fluocinolone acetonide (“FA”) insert for posterior segment uveitis (“Durasert three-year uveitis”) (formerly known as Medidur™), the Company’s lead product candidate, is in pivotal Phase 3 clinical trials, and ILUVIEN® for diabetic macular edema (“ILUVIEN”), the Company’s most recent <font style="WHITE-SPACE: nowrap">out-licensed</font> product, is sold directly in the U.S. and three European Union (“EU”) countries. Retisert®, which was approved by the FDA for the treatment of posterior segment uveitis, is sold by Bausch & Lomb Incorporated (“Bausch & Lomb”). The Company’s development programs are focused primarily on developing sustained release products that utilize its Durasert technology platform to deliver approved drugs to treat chronic diseases. The Company’s strategy includes developing products independently while continuing to leverage its technology platforms through collaborations and license agreements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> Durasert three-year uveitis, the Company’s most advanced development product candidate, is designed to treat chronic <font style="WHITE-SPACE: nowrap">non-infectious</font> uveitis affecting the posterior segment of the eye (“posterior segment uveitis”) for three years from a single administration. Injected into the eye in an office visit, this product candidate is a tiny micro-insert that delivers a micro-dose of a corticosteroid to the back of the eye on a sustained basis. The Company is developing Durasert three-year uveitis independently.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> The first of two Phase 3 clinical trials investigating Durasert three-year uveitis met its primary efficacy endpoint of prevention of recurrence of disease through six months with high statistical significance (p < 0.001, intent to treat analysis) and with safety data consistent with the known effects of ocular corticosteroid use. The same high statistical significance for efficacy and encouraging safety results were maintained through 12 months of <font style="WHITE-SPACE: nowrap">follow-up.</font> Due to the high level of statistical significance achieved, the Company plans to file its EU marketing approval application (“MAA”) based on data from the first Phase 3 clinical trial, rather than two clinical trials. The Company expects to file the MAA in June 2017. The second Phase 3 clinical trial completed its target enrollment of 150 patients at the end of September 2016. This clinical trial has the same clinical trial design and the same endpoint as the first Phase 3 clinical trial, and a <font style="WHITE-SPACE: nowrap">read-out</font> of its <font style="WHITE-SPACE: nowrap">top-line</font> results is expected in June 2017. Assuming favorable results, the Company plans to file a new drug application (“NDA”) with the FDA in the fourth quarter of calendar 2017. The Company’s new Durasert three-year uveitis inserter with a smaller diameter needle, and original inserter with a slightly larger diameter needle and simpler mechanism, were evaluated in a utilization study that will be filed in both the MAA and NDA. Both inserters met their primary endpoint of ease of intravitreal administration.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> ILUVIEN is an injectable, sustained-release micro-insert that provides three years of treatment of diabetic macular edema from a single injection. ILUVIEN is based on the same technology as the Durasert three-year uveitis insert, and delivers the same corticosteroid, FA. ILUVIEN was developed in collaboration with, and is licensed to and sold by, Alimera Sciences, Inc. (“Alimera”). The Company is entitled to a share of the net profits (as defined) from Alimera’s sales of ILUVIEN on a <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">quarter-by-quarter,</font></font> <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">country-by-country</font></font> basis. ILUVIEN has been sold directly in the United Kingdom (“U.K.”) and Germany since June 2013 and in the U.S. and Portugal since 2015, and also has marketing approvals in 14 other European countries. Alimera has sublicensed distribution, regulatory and reimbursement matters for ILUVIEN in Australia and New Zealand, Canada, Italy, Spain and numerous countries in the Middle East.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> The Company’s <font style="WHITE-SPACE: nowrap">FDA-approved</font> Retisert is an implant that provides sustained treatment of posterior segment uveitis for 30 months. Administered in a surgical procedure, Retisert delivers the same corticosteroid as the Durasert three-year <font style="WHITE-SPACE: nowrap">non-erodible</font> insert, but in a larger dose. Retisert was <font style="WHITE-SPACE: nowrap">co-developed</font> with, and is licensed to, Bausch & Lomb, and the Company receives royalties from its sales.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> The Company’s development programs are focused primarily on developing sustained release drug products using its proven Durasert technology platform to deliver small molecule drugs to treat uveitis, wet <font style="WHITE-SPACE: nowrap">age-related</font> macular degeneration (“AMD”), osteoarthritis and other diseases. A sustained-release surgical implant delivering a corticosteroid to treat pain associated with severe knee osteoarthritis that was jointly developed by the Company and Hospital for Special Surgery is currently being evaluated in an investigator-sponsored safety and tolerability study. The Company has minimized further development work of its Tethadur™ technology platform designed to deliver large molecules, such as biologics, both locally and systemically, in order to focus its resources on leveraging its proven Durasert technology for delivery of small molecules.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> The Company has financed its operations primarily from sales of equity securities and the receipt of license fees, milestone payments, research and development funding and royalty income from its collaboration partners. The Company has a history of operating losses and, to date, has not had significant recurring cash inflows from revenue. The Company believes that its cash, cash equivalents and marketable securities of $15.4 million at March 31, 2017, together with subsequent cash proceeds received from additional utilization of its <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">at-the-market</font></font> (“ATM”) equity program (refer to Note 8) and from existing collaboration agreements, will enable the Company to maintain its current and planned operations (including its two Durasert three-year uveitis Phase 3 clinical trials) through approximately the third quarter of fiscal 2018. This estimate excludes any potential receipts under the Alimera agreement. In order to extend the Company’s ability to fund operations beyond the third quarter of fiscal 2018, management’s plans include reducing or deferring operating expenses and/or accessing additional equity financing from the sale of its common stock through its ATM program or other financing transactions. The timing and extent of the Company’s implementation of these plans is expected to depend on the amount and timing of cash receipts from Alimera’s commercialization of ILUVIEN, proceeds from any future collaboration or other agreements and/or proceeds from any financing transactions. There is no assurance that the Company will receive significant, if any, revenues from Alimera’s commercialization of ILUVIEN or financing from any other sources.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the Company believes that recently issued and adopted pronouncements will not have a material impact on the Company’s financial position, results of operations and cash flows or do not apply to the Company’s operations.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> In May 2014, the FASB issued Accounting Standards Update <font style="WHITE-SPACE: nowrap">No. 2014-09,</font> <i>Revenue from Contracts with Customers </i>(Topic 606) (“ASU <font style="WHITE-SPACE: nowrap">2014-09”),</font> which requires an entity to recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP. In August 2015, the FASB issued ASU <font style="WHITE-SPACE: nowrap">2015-14,</font> which officially deferred the effective date of ASU <font style="WHITE-SPACE: nowrap">2014-09</font> by one year, while also permitting early adoption. As a result, ASU <font style="WHITE-SPACE: nowrap">2014-09</font> will become effective on July 1, 2018, with early adoption permitted on July 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the impact the adoption of this standard will have on its consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> In August 2014, the FASB issued ASU <font style="WHITE-SPACE: nowrap">2014-15,</font> <i>Presentation of Financial Statements – Going Concern</i>. ASU <font style="WHITE-SPACE: nowrap">2014-15</font> provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The new standard is effective for annual periods ending after December 15, 2016, and interim periods thereafter. As a result, ASU <font style="WHITE-SPACE: nowrap">2014-15</font> will become effective for the annual period ending June 30, 2017, and interim periods thereafter. The Company is evaluating the impact the adoption of this standard will have on its consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">  </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> In February 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">No. 2016-02,</font> <i>Leases</i>. The new standard establishes a <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">right-of-use</font></font> (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. As a result, ASU <font style="WHITE-SPACE: nowrap">2016-02</font> will become effective on July 1, 2019. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is evaluating the impact the adoption of this standard will have on its consolidated financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> In March 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">2016-09,</font> <i>Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</i>. ASU <font style="WHITE-SPACE: nowrap">2016-09</font> intends to simplify various aspects of how share-based payments are accounted for and presented in the financial statements. The main provisions include: all tax effects related to stock awards will now be recorded through the statement of operations instead of through equity, all <font style="WHITE-SPACE: nowrap">tax-related</font> cash flows resulting from stock awards will be reported as operating activities on the cash flow statement, and entities can make an accounting policy election to either estimate forfeitures or account for forfeitures as they occur. The amendments in ASU <font style="WHITE-SPACE: nowrap">2016-09</font> are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, and may be applied prospectively with earlier adoption permitted. As a result, ASU <font style="WHITE-SPACE: nowrap">2016-09</font> will become effective on July 1, 2017. The Company is evaluating the impact the amendment of this guidance will have on its consolidated financial statements.</p> <br class="Apple-interchange-newline" /> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16038000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2305000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	33000
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	20881000
CY2016Q2	us-gaap	Restructuring Reserve RestructuringReserve	187000
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-292213000
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	483000
CY2016Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2016Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000
CY2016Q2	psdv	Warrants Outstanding And Exercisable Weighted Average Exercise Price WarrantsOutstandingAndExercisableWeightedAverageExercisePrice	2.50
CY2016Q2	psdv	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	1678000
CY2016Q2	psdv	Warrants To Purchase Common Shares Outstanding And Exercisable WarrantsToPurchaseCommonSharesOutstandingAndExercisable	623605	shares
	dei	Entity Registrant Name EntityRegistrantName	PSIVIDA CORP.
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-9000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8121296	shares
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001314102
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1774000
	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2442000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-11000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1774000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	22000
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8611000
	us-gaap	Depreciation Depreciation	59000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12397000
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	542000
	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P9M
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M6D
	us-gaap	Revenues Revenues	6838000
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-424000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	71000
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	5584000
	us-gaap	Operating Expenses OperatingExpenses	19278000
	us-gaap	Net Income Loss NetIncomeLoss	-12369000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	5052000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12369000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	11203000
	us-gaap	Restructuring Charges RestructuringCharges	472000
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2153000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	99000
	dei	Trading Symbol TradingSymbol	PSDV
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10667000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	99000
	us-gaap	Share Based Compensation ShareBasedCompensation	1774000
	us-gaap	Royalty Revenue RoyaltyRevenue	730000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34238000	shares
	psdv	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	16243000
	psdv	Finite Lived Intangible Assets Foreign Currency Translation Of Accumulated Amortization FiniteLivedIntangibleAssetsForeignCurrencyTranslationOfAccumulatedAmortization	-1344000
	psdv	Warrants To Purchase Common Shares Expired WarrantsToPurchaseCommonSharesExpired	0	shares
	psdv	Exercise Price Of Expired Warrants ExercisePriceOfExpiredWarrants	0.00
	psdv	Marketable Securities Weighted Average Maturity MarketableSecuritiesWeightedAverageMaturity	P18D
	psdv	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-5000
	psdv	Noncash Unpaid Stock Issuance Costs NoncashUnpaidStockIssuanceCosts	152000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	86000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5695026	shares
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1549000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5746000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-12000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1549000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6357000
	us-gaap	Depreciation Depreciation	88000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15223000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	569000
	us-gaap	Revenues Revenues	1316000
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	635000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	41000
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	0
	us-gaap	Operating Expenses OperatingExpenses	16634000
	us-gaap	Net Income Loss NetIncomeLoss	-15160000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	10242000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15277000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	859000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-68000
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	372000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-63000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15318000
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-284000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	16868000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-25000
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	5000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-117000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11969000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	67000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16510000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16501000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	358000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10277000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	358000
	us-gaap	Share Based Compensation ShareBasedCompensation	1549000
	us-gaap	Royalty Revenue RoyaltyRevenue	944000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30787000	shares
	psdv	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	11168000
	psdv	Warrants To Purchase Common Shares Expired WarrantsToPurchaseCommonSharesExpired	552500	shares
	psdv	Exercise Price Of Expired Warrants ExercisePriceOfExpiredWarrants	5.00
	psdv	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	5000
	psdv	Noncash Unpaid Stock Issuance Costs NoncashUnpaidStockIssuanceCosts	0
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	756000
CY2016	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	-3514000
CY2016	psdv	Finite Lived Intangible Assets Foreign Currency Translation Of Accumulated Amortization FiniteLivedIntangibleAssetsForeignCurrencyTranslationOfAccumulatedAmortization	-3447000
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8121296	shares
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5140000
CY2017Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0
CY2017Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	372000
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1000
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5160000
CY2017Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	1000
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2346000
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3324000
CY2017Q1	us-gaap	Royalty Revenue RoyaltyRevenue	218000
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34366000	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5695026	shares
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	661000
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	644000
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2426000
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5139000
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	180000
CY2017Q1	us-gaap	Revenues Revenues	590000
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20000
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	5750000
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-5140000
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5053000
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	187000
CY2016Q1	us-gaap	Revenues Revenues	324000
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	21000
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	5420000
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-5041000
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5075000
CY2016Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-21000
CY2016Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	50000
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-12000
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5096000
CY2016Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	9000
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-34000
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3074000
CY2016Q1	us-gaap	Royalty Revenue RoyaltyRevenue	274000
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33538000	shares

Files In Submission

Name	View Source	Status
0001193125-17-162489-index-headers.html	Edgar Link	pending
0001193125-17-162489-index.html	Edgar Link	pending
0001193125-17-162489.txt	Edgar Link	pending
0001193125-17-162489-xbrl.zip	Edgar Link	pending
d347658d10q.htm	Edgar Link	pending
d347658dex311.htm	Edgar Link	pending
d347658dex312.htm	Edgar Link	pending
d347658dex321.htm	Edgar Link	pending
d347658dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
psdv-20170331.xml	Edgar Link	completed
psdv-20170331.xsd	Edgar Link	pending
psdv-20170331_cal.xml	Edgar Link	unprocessable
psdv-20170331_def.xml	Edgar Link	unprocessable
psdv-20170331_lab.xml	Edgar Link	unprocessable
psdv-20170331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EYPT
EyePoint Pharmaceuticals, Inc. Stock $eypt

2017 Q2 Form 10-Q Financial Statement

#000119312517162489 Filed on May 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EYPT EyePoint Pharmaceuticals, Inc. Stock $eypt

2017 Q2 Form 10-Q Financial Statement

#000119312517162489 Filed on May 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EYPT
EyePoint Pharmaceuticals, Inc. Stock $eypt